Should I buy or sell Senti Biosciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Senti Biosciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SNTI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNTI, but not buy additional shares or sell existing shares. View SNTI analyst ratings or view top-rated stocks .

What is Senti Biosciences' stock price target for 2024?

3 brokerages have issued 12 month target prices for Senti Biosciences' shares. Their SNTI share price targets range from $2.00 to $6.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 809.1% from the stock's current price. View analysts price targets for SNTI or view top-rated stocks among Wall Street analysts .

How have SNTI shares performed in 2023?

Senti Biosciences' stock was trading at $1.41 at the beginning of 2023. Since then, SNTI stock has decreased by 68.8% and is now trading at $0.44. View the best growth stocks for 2023 here .

Are investors shorting Senti Biosciences?

Senti Biosciences saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,500,000 shares, an increase of 260.1% from the October 31st total of 416,500 shares. Based on an average trading volume of 2,530,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 5.7% of the shares of the stock are short sold. View Senti Biosciences' Short Interest .

When is Senti Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our SNTI earnings forecast .

What ETF holds Senti Biosciences' stock ?

ARK Genomic Revolution ETF holds 1,882,161 shares of SNTI stock, representing 0.08% of its portfolio.

Who are Senti Biosciences' major shareholders?

Senti Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include TD Asset Management Inc (0.54%). View institutional ownership trends .

How do I buy shares of Senti Biosciences?

Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Senti Biosciences Stock Price, News & Analysis (NASDAQ:SNTI)

$0.44

+0.01 (+2.33%)

(As of 12/1/2023 ET)

Compare

Today's Range: $0.41
▼
$0.45
50-Day Range: $0.28
▼
$0.68
52-Week Range: $0.27
▼
$2.37

Volume: 202,649 shs
Average Volume: 7.35 million shs
Market Capitalization: $19.60 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Senti Biosciences MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 809.1% Upside
$4.00 Price Target
Short Interest: Bearish
5.71% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.44
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.59) to ($1.11) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

634th out of 952 stocks

Biological Products, Except Diagnostic Industry

106th out of 164 stocks

3.2

Analyst's Opinion

Consensus Rating
Senti Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Senti Biosciences has a forecasted upside of 809.1% from its current price of $0.44.
Amount of Analyst Coverage
Senti Biosciences has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.71% of the float of Senti Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Senti Biosciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Senti Biosciences has recently increased by 260.14%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Senti Biosciences does not currently pay a dividend.
Dividend Growth
Senti Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SNTI.

3.0

News and Social Media Coverage

News Sentiment
Senti Biosciences has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Senti Biosciences this week, compared to 0 articles on an average week.
Search Interest
9 people have searched for SNTI on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.
MarketBeat Follows
2 people have added Senti Biosciences to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Senti Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.50% of the stock of Senti Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 27.37% of the stock of Senti Biosciences is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Senti Biosciences are expected to grow in the coming year, from ($1.59) to ($1.11) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Senti Biosciences is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Senti Biosciences is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Senti Biosciences has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Senti Biosciences Stock (NASDAQ:SNTI)

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

SNTI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SNTI Stock News Headlines

November 24, 2023 | finanznachrichten.de

Senti Biosciences, Inc.: Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates

November 13, 2023 | finance.yahoo.com

Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 11, 2023 | morningstar.com

Senti Biosciences Inc SNTI

November 7, 2023 | msn.com

Why Is Cell & Gene Therapy-Focused Senti Biosciences Stock Trading Higher Today?

November 7, 2023 | msn.com

Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today?

November 7, 2023 | msn.com

Why Is Senti Biosciences (SNTI) Stock Up 140% Today?

November 6, 2023 | finance.yahoo.com

Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

October 31, 2023 | finance.yahoo.com

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting

October 9, 2023 | bizjournals.com

Gene and cell therapy startup GeneFab takes over Senti Biosciences' Alameda manufacturing facility

September 27, 2023 | investing.com

Shanti Overseas India Ltd (SNTI)

September 27, 2023 | finance.yahoo.com

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting

September 26, 2023 | finance.yahoo.com

Senti Bio to Participate in Upcoming Conferences

August 15, 2023 | msn.com

Chardan Capital Reiterates Senti Biosciences (SNTI) Buy Recommendation

August 11, 2023 | finanznachrichten.de

Senti Biosciences, Inc.: Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates

August 11, 2023 | finance.yahoo.com

Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates

August 11, 2023 | finance.yahoo.com

Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates

August 10, 2023 | finance.yahoo.com

Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners

June 5, 2023 | finance.yahoo.com

Here's Why Senti Biosciences (NASDAQ:SNTI) Must Use Its Cash Wisely

May 11, 2023 | msn.com

Chardan Capital Maintains Senti Biosciences (SNTI) Buy Recommendation

May 9, 2023 | finance.yahoo.com

Senti Bio Announces First Quarter 2023 Results and Pipeline Updates

May 2, 2023 | finance.yahoo.com

Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting

April 17, 2023 | finance.yahoo.com

Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting

April 14, 2023 | finance.yahoo.com

Senti Bio to Participate in Upcoming Investor Conferences

March 24, 2023 | markets.businessinsider.com

Expert Ratings for Senti Biosciences

March 24, 2023 | markets.businessinsider.com

Morgan Stanley Reaffirms Their Hold Rating on Senti Biosciences (SNTI)

See More Headlines

Receive SNTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SNTI
CUSIP: N/A
CIK: 1854270
Web: www.sentibio.com
Phone: 650-239-2030
Fax: N/A
Employees: 122
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $6.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +809.1%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,210,000.00
Net Margins: -2,692.82%
Pretax Margin: -3,609.96%
Return on Equity: -63.39%
Return on Assets: -43.10%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.81
Quick Ratio: 7.81

Sales & Book Value

Annual Sales: $4.29 million
Price / Sales: 4.57
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.86 per share
Price / Book: 0.24

Miscellaneous

Outstanding Shares: 44,540,000
Free Float: 38,977,000
Market Cap: $19.60 million
Optionable: Not Optionable
Beta: 2.51

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Timothy K. Lu M.D. (Age 42)
Ph.D., Co-founder, CEO, President & Director
Comp: $811.26k
Dr. James J. Collins Ph.D. (Age 57)
Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director
Comp: $41.49k
Dr. Deborah A. Knobelman Ph.D. (Age 49)
CFO, Head of Corporate Development & Treasurer
Comp: $600.22k
Ms. Susan D. Berland (Age 68)
Senior Financial Executive & Independent Director
Comp: $54.23k
Dr. Kanya Rajangam M.D. (Age 50)
Ph.D., Head of Research & Development and Chief Medical Officer
Comp: $679.71k
Dr. Wilson Wong Ph.D.
Scientific Co-Founder & Member of Scientific Advisory Board
Mr. Mike Rhee
Senior VP of Legal Affairs & Corporate Secretary
Mr. Martin A. Giedlin Ph.D.
Senior Vice President of Science Development
Susan Kahlert
Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SNTI Stock Analysis - Frequently Asked Questions

Should I buy or sell Senti Biosciences stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Senti Biosciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SNTI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNTI, but not buy additional shares or sell existing shares.
View SNTI analyst ratings or view top-rated stocks.
What is Senti Biosciences' stock price target for 2024?: 3 brokerages have issued 12 month target prices for Senti Biosciences' shares. Their SNTI share price targets range from $2.00 to $6.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 809.1% from the stock's current price.
View analysts price targets for SNTI or view top-rated stocks among Wall Street analysts.
How have SNTI shares performed in 2023?: Senti Biosciences' stock was trading at $1.41 at the beginning of 2023. Since then, SNTI stock has decreased by 68.8% and is now trading at $0.44.
View the best growth stocks for 2023 here.
Are investors shorting Senti Biosciences?: Senti Biosciences saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,500,000 shares, an increase of 260.1% from the October 31st total of 416,500 shares. Based on an average trading volume of 2,530,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 5.7% of the shares of the stock are short sold.
View Senti Biosciences' Short Interest.

When is Senti Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our SNTI earnings forecast.
What ETF holds Senti Biosciences' stock ?: ARK Genomic Revolution ETF holds 1,882,161 shares of SNTI stock, representing 0.08% of its portfolio.
Who are Senti Biosciences' major shareholders?: Senti Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include TD Asset Management Inc (0.54%).
View institutional ownership trends.
How do I buy shares of Senti Biosciences?: Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SNTI) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Senti Biosciences Stock Price, News & Analysis (NASDAQ:SNTI)

Senti Biosciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Senti Biosciences Stock (NASDAQ:SNTI)

SNTI Stock Price History

SNTI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

SNTI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™